| Description |
Tumor organoids are important tools for cancer research but current models have drawbacks which limit its applications in clinic. Here we developed a fast, efficient and complex culture system (IPTO: individualized patient tumor organoid) which maintains the cellular and molecular pathology of human brain cancers. We showed that this model can be used to culture a wide range of human cancers in the central nervous system (CNS), including brain metastasis. Histology, epigenome and scRNA-seq analysis demonstrated that IPTOs model recapitulates cellular heterogeneity and molecular feature of parental tumors. Most importantly, we further showed that the IPTO model predicts patients drug responses in a prospective clinical study. We also showed that IPTO can be used to reveal drug response and resistance mechanisms. The IPTO model represents a major breakthrough in preclinic modeling of human cancers, which provides a clear path toward personalized cancer therapy. |